The retroviral oncogene, v-fms, was acquired by genetic recombination between a feline leukemia virus (FeLV) and proto- oncogene sequences (c-fms) from normal cat cells. We demonstrated that the c-fms proto-oncogene encodes a receptor for the mononuclear phagocyte colony stimulating factor, CSF-1 (M-CSF). To date, this is the only system in which a hematopoietic growth factor and its receptor have both been cloned and characterized. Expression of c-fms at high levels in macrophages or after retroviral-mediated transfer into cultured fibroblasts does not lead to transformation, whereas v-fms transforms fibroblasts, CSF-1-dependent macrophages, and IL-3- dependent myeloid cell lines. An analysis of mutant c-fms and chimeric v-fms/c-fms genes suggested that two genetic alterations in c-fms are required to fully activate its oncogenic potential: (1) an activating mutation in the body of the gene that renders the receptor tyrosine kinase CSF-1-independent, and (2) elimination of a single C-terminal tyrosine residue (tyr969) that is likely to be a negative regulatory site of receptor phosphorylation. Additional chimeric and mutant receptor molecules will be used to pinpoint the site(s) of activating mutation(s), to identify sites of autophosphorylation, and to define putative target residues for protein kinase C phosphorylation that mediate receptor down modulation in response to phorbol esters. The structure and function of CSF-1 and its ability to transform cells by an autocrine mechanism when cotransfected with the c- fms gene will be studied. The ability of the CSF-1 receptor to program differentiative and proliferative responses will be evaluated after introducing the c-fms gene into committed myeloid precursors in vitro. Parallel approaches will assess the ability of the v-fms and CSF-1 genes to transform early myeloid progenitors in vitro and to contribute to leukemias in vivo after gene transfer into murine hematopoietic stem cells. The human c-fms and CSF-1 genes, both closely linked on human chromosome 5q, will be evaluated for specific rearrangements associated with acute myeloid leukemias. Studies at the genetic level will be complemented by biochemical approaches to identify defects in receptor function affecting CSF-1 induced kinase activity, receptor turnover, and down modulation. Our studies are likely to provide mechanistic information about normal hematopoiesis and to pinpoint defects in growth factor -- receptor interactions that contribute to leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Unknown (R35)
Project #
5R35CA047064-02
Application #
3479638
Study Section
(SRC)
Project Start
1988-06-01
Project End
1995-05-31
Budget Start
1989-06-01
Budget End
1990-05-31
Support Year
2
Fiscal Year
1989
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Afar, D E; McLaughlin, J; Sherr, C J et al. (1995) Signaling by ABL oncogenes through cyclin D1. Proc Natl Acad Sci U S A 92:9540-4
Roussel, M F; Theodoras, A M; Pagano, M et al. (1995) Rescue of defective mitogenic signaling by D-type cyclins. Proc Natl Acad Sci U S A 92:6837-41
Okuda, T; Shurtleff, S A; Valentine, M B et al. (1995) Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 85:2321-30
Quelle, D E; Ashmun, R A; Hannon, G J et al. (1995) Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene 11:635-45
Okuda, T; Hirai, H; Valentine, V A et al. (1995) Molecular cloning, expression pattern, and chromosomal localization of human CDKN2D/INK4d, an inhibitor of cyclin D-dependent kinases. Genomics 29:623-30
Hirai, H; Roussel, M F; Kato, J Y et al. (1995) Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 15:2672-81
Sherr, C J (1995) Mammalian G1 cyclins and cell cycle progression. Proc Assoc Am Physicians 107:181-6
Polyak, K; Kato, J Y; Solomon, M J et al. (1994) p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8:9-22
Roussel, M F; Davis, J N; Cleveland, J L et al. (1994) Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1. Oncogene 9:405-15
Matsushime, H; Quelle, D E; Shurtleff, S A et al. (1994) D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 14:2066-76

Showing the most recent 10 out of 50 publications